Syros Pharmaceuticals Inc. (NASDAQ: SYRS) open the trading on May 18, 2021, with a bit cautious approach as it glided -0.38% to $5.28. During the day, the stock rose to $5.64 and sunk to $5.18 before settling in for the price of $5.30 at the close. Taking a more long-term approach, SYRS posted a 52-week range of $4.75-$15.65.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 116.50%. Meanwhile, its Annual Earning per share during the time was -3.60%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 2.70%. This publicly-traded company’s shares outstanding now amounts to $61.38 million, simultaneously with a float of $58.84 million. The organization now has a market capitalization sitting at $318.54 million. At the time of writing, stock’s 50-day Moving Average stood at $6.94, while the 200-day Moving Average is $9.48.
If we measure the efficiency of the company that is accounted for 103 employees. It has generated 146,534 per worker during the last fiscal year. Meanwhile, its income per employee was -815,903. The stock had 1.34 Receivables turnover and 0.08 Total Asset turnover. For the Profitability, stocks operating margin was -545.27 and Pretax Margin of -556.80.
Syros Pharmaceuticals Inc. (SYRS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Syros Pharmaceuticals Inc.’s current insider ownership accounts for 1.40%, in contrast to 88.60% institutional ownership. According to the most recent insider trade that took place on Mar 15, this organization’s Chief Scientific Officer sold 3,628 shares at the rate of 9.47, making the entire transaction reach 34,372 in total value, affecting insider ownership by 0. Preceding that transaction, on Feb 16, Company’s Director sold 3,750 for 12.05, making the whole transaction’s value amount to 45,188. This particular insider is now the holder of 321,711 in total.
Syros Pharmaceuticals Inc. (SYRS) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 3/31/2021 suggests? It has posted -$0.23 earnings per share (EPS) beating the forecaster’s viewpoint (set at -$0.46) by $0.23. This company achieved a net margin of -556.80 while generating a return on equity of -99.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
Syros Pharmaceuticals Inc.’s EPS increase for this current 12-month fiscal period is 2.70% and is forecasted to reach -1.83 in the upcoming year.
Syros Pharmaceuticals Inc. (NASDAQ: SYRS) Trading Performance Indicators
Let’s observe the current performance indicators for Syros Pharmaceuticals Inc. (SYRS). It’s Quick Ratio in the last reported quarter now stands at 8.30. The Stock has managed to achieve an average true range (ATR) of 0.46. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 18.20.
In the same vein, SYRS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.65, a figure that is expected to reach -0.37 in the next quarter, and analysts are predicting that it will be -1.83 at the market close of one year from today.
Technical Analysis of Syros Pharmaceuticals Inc. (SYRS)
[Syros Pharmaceuticals Inc., SYRS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 46.54% While, its Average True Range was 0.47.
Raw Stochastic average of Syros Pharmaceuticals Inc. (SYRS) in the period of the previous 100 days is set at 4.93%, which indicates a major fall in contrast to 27.86% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 44.83% that was lower than 81.59% volatility it exhibited in the past 100-days period.